CG Oncology Inc

CG Oncology insider purchases reveal executive confidence and a possible commercialization push—learn how this could support shares and signal future biotech milestones.

CEO buys CG Oncology shares at $1.72, a strong insider signal. Investors should watch upcoming trials, regulatory milestones, and market sentiment for upside.

CEO CG Oncology buy shows insider confidence amid rising Nasdaq shares—learn how option exercises and insider moves signal future value for investors.

CG Oncology insider trades reveal Mulay James’ buy‑low/sell‑high strategy and large option stake, signaling confidence while managing liquidity and future upside.